Chronic lymphocytic leukemia

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Hallek, Michael ^a   Pflug, Natali ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemoimmunotherapy; CLL; MRD; Therapy

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; BENDAMUSTINE; CD20 ANTIGEN; CD23 ANTIGEN; CD37 ANTIGEN; CD40 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; GA 101; LENALIDOMIDE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER REGRESSION; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOPENIA; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; SKIN DISEASE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; TUMOR MICROENVIRONMENT; VASCULAR DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUGS, INVESTIGATIONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649373387     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq373     Document Type: Conference Paper

References (81)

1. Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38 (Suppl 2): S41-S61.
2. Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol 1997; 8 (Suppl 1): 93-101.
3. CLL trialists collaborative group. Chemotherapeutic options in chronic lymhocytic leukemia. J Natl Cancer Inst 1999; 91: 861-868.
4. Anaissie EJ, Kontoyiannis DP, O'Brien S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559-566.
5. Plunkett W, Gandhi V, Huang P et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20(5 Suppl 7): 2-12.
6. Rai KR, Peterson PL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
7. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.
8. Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-2325.
9. Johnson S, Smith AG, Löffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432-1438.
10. Steurer M, Pall M, Richards S et al. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2006; 3: CD004270.
11. Eichhorst BF, Busch R, Stilgenbauer S et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382-3391.
12. Robak T, Bloński JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first- line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-2729.
13. Knauf WU, Lissichkov T, Adaoud A et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. Blood (ASH Annual Meeting Abstracts) 2007; 110: 2043.
14. Ö sterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leucemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574.
15. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
16. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
17. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
18. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
19. Eichhorst BF, Busch R, Stauch M et al. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a phase III study of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 2007; 110: 629.
20. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
21. Stilgenbauer S, Senz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001.
22. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326-1331.
23. O'Brien S, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 2001; 19: 2165-2170.
24. Bellosillo B, Villamor N, Colomer D et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-2843.
25. Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 2004; 5 (Suppl 1): S20-S30.
26. Stilgenbauer S, Kröber A, Busch R et al. 17p deletion predicts for inferior overall survival after fludarabine - based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. (Blood (ASH Annual Meeting Abstracts)) Blood 2005; 106: 715.
27. Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793-798.
28. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
29. Stilgenbauer S, Eichhorst BF, Busch R et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC) - comprehensive analysis of the CLL4 trial of the GCLLSG. Blood (ASH Annual Meeting Abstracts) 2008; 112: 2089.
30. Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010; 28: 1863-1869.
31. Robak T, Blonski JZ, Gora-Taylor J et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 2006; 108: 473-479.
32. Bosch F, Ferrer A, López-Guillermo A et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-984.
33. Bosch F, Ferrer A, Villamor N et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008; 14: 155-161.
34. Schulz H, Klein SK, Rehwald U et al. Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-3120.
35. Byrd JC, Peterson BL, Morrison VA et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6-14.
36. Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49-53.
37. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078.
38. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
39. Hallek M, Fingerle-Rowson G, Fink A-M et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood (ASH Annual Meeting Abstracts) 2009; 114: 535.
40. Foon KA, Noyiadzis M, Land SR et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 498-503.
41. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
42. Lamanna N, Jurcic JG, Noy A et al. Sequential therapy with fludarabine, highdose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27: 491-497.
43. Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4578-4584.
44. Parikh SA, Keating M, O'Brien S et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in highrisk chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114: 208.
45. Reynolds C, Di Bella N, Lyons RM et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab Vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2008; 112: 327.
46. Kay NE, Wu W, Kabat B et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 2010; 116: 2180-2187.
47. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 2008; 112: 330.
48. Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 2009; 114: 205.
49. Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-2247.
50. Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory Bcell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024-7031.
51. Faderl S, Thomas DA, O'Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413-3415.
52. Faderl S, Ferrajoli A, Wierda W et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116: 2360-2365.
53. Byrd JC, O'Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13: 4448-4455.
54. Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 115: 489-495.
55. Byrd JC, Castro J, O'Brien S et al. Comparison of results from a phase 1/2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood (ASH Annual Meeting Abstracts) 2006; 108: 32.
56. Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349.
57. Ferrajoli A, Lee BN, Sclette EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
58. Ferrajoli A, O'Brien S, Wierda W et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytica leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008; 112: 45.
59. Chen C, Paul H, Xu W et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008; 112: 44.
60. Ferrajoli A, Badoux XC, O'Brien S et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2009; 114: 206.
61. Brown JR, Abramson JS, Hochberg EP et al. A phase I study of lenalidomide in combination with fludarabine-rituximab in previously untreated CLL/SLL. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3426.
62. Egle A, Steurer M, Melchardt T et al. The REVLIRIT CLL5 AGMT Study - a phase I/II trial combining fludarabine/rituximab with escalating doses of lenalidomide followed by rituximab/lenalidomide in untreated chronic lymphocytic leukemia (CLL): results of a planned interim analysis. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3453.
63. Phelps MA, Lin TS, Johnson AJ et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637-2645.
64. Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404.
65. Lin TS, Ruppert AS, Johnson AJ et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-6018.
66. Hallek M, Fingerle-Rowson G, Fink A-M et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008; 112: 325.
67. O'Brien S, Moore JO, Boyd TE et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-1120.
68. Osterborg A, Kipps TJ, Mayer J et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood (ASH Annual Meeting Abstracts) 2008; 112: 328.
69. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28: 1749-1755.
70. Wierda WG, Kipps TJ, Dürig J et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood (ASH Annual Meeting Abstracts) 2009; 114: 207.
71. Morschhauser F, Cartron G, Lamy T et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114: 884.
72. Schweighofer CD, Ritgen M, Eichhorst BF et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009; 144: 95-98.
73. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979.
74. Montillo M, Cafro AM, Tedeschi A et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695-700.
75. O'Brien SM, kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657-2663.
76. Lin TS, Donohue KA, Lucas MS et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood (ASH Annual Meeting Abstracts) 2007; 110: 755.
77. Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093-1101.
78. Boettcher S, Fischer K, Stilgenbauer S et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 Trial. Blood (ASH Annual Meeting Abstracts) 2008; 112: 326.
79. Rawstron AC, villamor N, Ritgen M et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956-964.
80. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older patients. J Clin Oncol 1998; 16: 1582-1587.
81. Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12-17.